Vascular Fundus Changes in Patients With High Probability of Chronic Cerebrospinal Venous Insufficiency (CCSVI)

Sponsor
Genetic Disease Investigators (Other)
Overall Status
Completed
CT.gov ID
NCT01356134
Collaborator
Optos, PLC (Industry)
60
1
47
1.3

Study Details

Study Description

Brief Summary

The investigators propose that evidence of chronic cerebrospinal venous insufficiency (CCSVI) may be evident in the vasculature of the fundus. The investigators will be examining fundi of multiple sclerosis patients and Ehlers-Danlos patients to see if evidence of CCSVI can be found in these patients having high risk for CCSVI. The investigators will read the fundus photos, compared to age-matched normals in a "blind" fashion.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Chronic Cerebrospinal Venous Insufficiency (CCSVI) has been proposed as the cause of numerous neurodegenerative diseases of the brain. CCSVI is the result of poor drainage of blood (and cerebral spinal fluid to some degree) from weakened or stenosed veins usually located in the cervical area (most notably the internal jugular veins). Although current focus and treatment of CCSVI is on multiple sclerosis, CCSVI has also been implicated as a potential cause of Alzheimer's disease and Parkinson's Disease. Additionally, patients with Ehlers-Danlos Syndrome (EDS) -- a disorder of connective tissue -- are more prone to developing multiple sclerosis than the general population. Many EDS patients are known to have weakened and abnormal blood vessels and 40 - 70% of EDS patients develop autonomic dysfunction in addition to numerous other symptoms found in patients with CCSVI. In the small subset of EDS and multiple sclerosis patients seen at Total Eye Care, the investigators have noticed a vascular irregularity (using the optomapĀ® and examining the results under high magnification) which offers credence to the theory of CCSVI. Such objective data has been elusive, excepting for fMRI, ultrasound (to a limited degree) and venous angioplasty results. Current treatment of CCSVI involves the ballooning and sometimes stenting, of abnormally stenosed veins. The treatment of CCSVI offers hope to many patients suffering from multiple sclerosis. Although CCSVI research is in its infancy, many doctors believe that CCSVI is a significant portion of the solution to patients with neurodegenerative diseases of the brain. Because CCSVI is a vascular disorder, the investigators hypothesize that the investigators are able to screen candidates for CCSVI via the optomapĀ®.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    60 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Cross-Sectional
    Official Title:
    Vascular Fundus Changes in Patients With High Probability of CCSVI (Chronic Cerebrospinal Venous Insufficiency)
    Study Start Date :
    May 1, 2011
    Actual Primary Completion Date :
    Apr 1, 2015
    Actual Study Completion Date :
    Apr 1, 2015

    Arms and Interventions

    Arm Intervention/Treatment
    Multiple sclerosis and or Ehlers-Danlos

    Patients with suspected or confirmed cases of Ehlers Danlos Syndrome and or Multiple Sclerosis

    Age matched normals

    Age matched normals

    Outcome Measures

    Primary Outcome Measures

    1. Fundus: venous engorgement/beading [Baseline]

      Abnormal vessel appearance in fundi may include venous engorgement and beading, abnormal A/V ratio, blurred disc margins, papilledema, dot hemorrhages or exudates.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • age matched normals

    • patients with diagnosed or suspected Ehlers-Danlos Syndrome and/or diagnosed or suspected Multiple Sclerosis ("CIS")

    Exclusion Criteria:
    • diabetics and patients unable to sit in position for testing are excluded

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Total Eye Care Colleyville Texas United States 76034

    Sponsors and Collaborators

    • Genetic Disease Investigators
    • Optos, PLC

    Investigators

    • Study Director: Diana L Driscoll, O.D., Genetic Disease Investigators
    • Principal Investigator: Richard A Driscoll, O.D., Genetic Disease Investigators
    • Study Chair: Clair A Francomano, M.D., Harvey Institute for Human Genetics

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    Diana Driscoll, O.D., Principal Investigator, Genetic Disease Investigators
    ClinicalTrials.gov Identifier:
    NCT01356134
    Other Study ID Numbers:
    • 61/3527
    First Posted:
    May 19, 2011
    Last Update Posted:
    Apr 3, 2015
    Last Verified:
    Apr 1, 2015
    Keywords provided by Diana Driscoll, O.D., Principal Investigator, Genetic Disease Investigators
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 3, 2015